Published in Medical Letter on the CDC and FDA, July 9th, 2006
In a recently published article, scientists in Taiwan conducted a study "to examine clinical outcomes in Asian patients with schizophrenia receiving monotherapy with olanzapine, risperidone, or typical antipsychotics in naturalistic settings. In this report, data from the first 12 months of the prospective, observational, three-year Intercontinental Schizophrenia Outpatient Health Outcomes study are presented for patients from participating Asian countries (Korea, Taiwan, and Malaysia) who were started on, or switched to, monotherapy with olanzapine (n=484),...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA